SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
8-K	Sep 18, 2026	Sep 18, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
10-Q	Aug 11, 2026	Aug 11, 2026	View filing
8-K	Aug 11, 2026	Aug 11, 2026	View filing
8-K	Jul 31, 2026	Jul 31, 2026	View filing
8-K	Jul 31, 2026	Jul 31, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
DFAN14A	Jul 28, 2026	Jul 28, 2026	View filing
DFAN14A	Jul 24, 2026	Jul 23, 2026	View filing
DEFA14A	Jul 22, 2026	Jul 22, 2026	View filing
DFAN14A	Jul 22, 2026	Jul 22, 2026	View filing
DEFA14A	Jul 20, 2026	Jul 20, 2026	View filing
8-K	Jul 20, 2026	Jul 20, 2026	View filing
DEFA14A	Jul 20, 2026	Jul 20, 2026	View filing
DEFA14A	Jul 20, 2026	Jul 20, 2026	View filing
DFAN14A	Jul 17, 2026	Jul 17, 2026	View filing
DEFA14A	Jul 14, 2026	Jul 14, 2026	View filing
DEFA14A	Jul 14, 2026	Jul 14, 2026	View filing
4	Jul 10, 2026	Jul 10, 2026	View filing
DFAN14A	Jul 9, 2026	Jul 8, 2026	View filing
DEFA14A	Jul 8, 2026	Jul 8, 2026	View filing
DEFA14A	Jul 8, 2026	Jul 8, 2026	View filing
DEFA14A	Jul 6, 2026	Jul 6, 2026	View filing
DFAN14A	Jul 6, 2026	Jul 6, 2026	View filing
DEFA14A	Jul 6, 2026	Jul 6, 2026	View filing

About Seer, Inc.

Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.

Redwood City, CA

124 employees

seer.bio

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Omid C. Farokhzad

View full financials